Longevity products need smarter regulation

Supplements, drugs, and diagnostic tests targeting biological aging fall into a grey zone in many countries. They are often classified neither as medicines nor as ordinary food products. This makes it difficult to evaluate and regulate them scientifically. The analysis, published in Science, argues that existing regulatory frameworks were not designed for products that target aging as their primary endpoint.

Aging as a recognised disease target

A central argument is that regulators such as the US FDA do not officially recognise aging as a condition for which a treatment can be approved. This creates a deadlock: companies cannot generate evidence through the standard clinical route, and without that route, products cannot receive formal approval. The result is that many products reach the market without robust evidence of efficacy.

At the same time, regulatory adaptation could open space for genuine innovation. The authors suggest that new approval pathways are conceivable, for example trials using biological aging markers as endpoints rather than a specific disease. That would require such markers to be scientifically validated and broadly recognised.

Consumer protection as an urgent concern

The analysis also raises a consumer dimension. People are already spending large sums on products claiming to extend lifespan or slow biological aging. Without adequate regulation, there is little protection against misleading claims. That is not only an individual problem: it also erodes trust in legitimate longevity research.

Publication in Science gives this debate scientific weight. Whether and how regulators will respond remains uncertain. But the question of how longevity innovation should be governed is urgent and far from settled.

Read the original article